Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02)

Part A:

Inclusion Criteria:

* Radiographic evidence of measurable disease (by Response Evaluation Criteria In Solid Tumors \[RECIST\]) and either:

  * Advanced epithelial ovarian cancer with serous or endometrioid histology, as confirmed by previous biopsy or,
  * ertafolide scan positive ovarian cancer, primary peritoneal cancer or adenocarcinoma of the endometrium.
* Prior treatment with platinum and/or taxane compounds.
* Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2.
* At least 4 weeks from prior therapy and recovered from associated acute toxicities.
* Adequate bone marrow reserve, renal, and hepatic function.
* Negative serum pregnancy test for women of childbearing potential and willingness to practice contraceptive methods.

Exclusion Criteria:

* Serious comorbidities (as determined by the Principal Investigator).
* Women who are pregnant or lactating.
* Symptomatic central nervous system (CNS) metastasis.
* Prior radiation therapy to assessable disease, unless disease progression is confirmed at that site.
* Requires palliative radiotherapy at time of study entry.
* Unable to tolerate conditions for radionuclide imaging.
* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational.
* Those who have been administered another radiopharmaceutical that would interfere with the assessment of 99mTc-ertafolide scan.

Part B:

Inclusion Criteria:

* Radiographic evidence of measurable disease (by RECIST criteria)
* ertafolide scan positive recurrent or persistent epithelial ovarian, primary fallopian tube, or peritoneal cancer.
* Prior treatment with platinum compounds, but not more than 4 prior cytotoxic chemotheraputic regimens.
* ECOG Performance status of 0-2.
* At least 3 weeks from prior cytotoxic therapy and recovered from associated acute toxicities.
* Adequate bone marrow reserve, renal, and hepatic function.
* Negative serum pregnancy test for women of childbearing potential and willingness to practice contraceptive methods.

Exclusion Criteria:

* Serious comorbidities (as determined by the Principal Investigator).
* Women who are pregnant or lactating.
* Symptomatic CNS metastasis.
* Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational.
* Those who have had prior therapy with Vinorelbine or vinca-containing compounds.